Recommended

New webinar with Fujifilm: Monocyte activation test (MAT): Insight into examining regulations and markets prospects
New webinar: The path to optimisation in pharmaceutical microbiology
Join our webinar: An alternative medium to support sterility testing using the Growth Direct® Rapid Sterility System
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps
article

Formulation, Development & Delivery In-Depth Focus 2020

In this in-depth focus find out about the development of a vaccine regimen to tackle Ebola and how a novel cannabinoid formulation has been developed to treat glioblastoma.

    To read this In-Depth Focus in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Charles River and Becton Dickinson

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    • Developing a preventive vaccine regimen to tackle Ebola
      Earlier this year, Johnson & Johnson announced the first major regulatory approval of a vaccine developed by Janssen for the prevention of Ebola. Nikki Withers spoke with the Global Head of Vaccines, Johan Van Hoof, to discover what technologies were used and how they are now being leveraged to develop a vaccine candidate for the prevention of COVID-19.
    • A novel cannabinoid formulation for glioblastoma treatment
      Earlier this year, MGC Pharmaceuticals, in collaboration with the Slovenian National Institute of Biology (NIB) and the Neurosurgery Department at the University Medical Centre in Ljubljana, Slovenia, announced successful research results for their novel cannabinoid formulation, which has been developed for the treatment of glioblastoma. This article highlights the key study findings and their future research plans.